Abdulrahman Nasiri: Most Important Concepts and the Clinical Shift the COBRRA Trial Brings to Practice
Abdulrahman Nasiri, Assistant Professor of Medicine and Hematology at Imam Mohammad Ibn Saud Islamic University, shared a post on LinkedIn:
”In preparation for my upcoming Grand Rounds presentation, I’ve put together these slides translating the recent COBRRA trial (NEJM 2026) titled:
‘Settling the DOAC Debate in Acute VTE’.
For years, major clinical guidelines haven’t recommended one DOAC over another due to a lack of head-to-head randomized trials.
Here are the most important concepts and the clinical shift this trial brings to our practice:
- Identical Efficacy: Both Apixaban and Rivaroxaban demonstrated an identical ~1% rate of recurrent VTE.
- Superior Safety: Apixaban cut the risk of clinically relevant bleeding by more than half and drove an 84% reduction in major bleeding.
- The Dosing Hypothesis: Why the difference? The bleeding divergence explodes in the first 3 weeks.
Rivaroxaban requires a high-dose induction phase that is three times longer than Apixaban (21 days vs. 7 days).
I am sharing the presentation here. Please feel free to use and adapt these slides for your own reference, clinical discussions, or teaching.”
Stay updated with Hemostasis Today.
-
Apr 28, 2026, 16:26Andrew Zapfel: The ASH’s Consortium on Newborn Screening in Africa Brought Together Over 40 People From 10 Countries
-
Apr 28, 2026, 16:22Beth Fernandes: Bringing Alaska’s First Civilian Medevac Whole Blood Program To Life
-
Apr 28, 2026, 15:47Dianne E. van der Wal: How Rat and Human Platelet Vesicles Are Different
-
Apr 28, 2026, 15:14Elaheh Mansouri: Platelet Clumping Is a Common Pre-Analytical and Analytical Challenge in Haematology
-
Apr 28, 2026, 15:11Hans Vrielink: Honoured to Receive the Cohn the Laval Award at the ASFA/WAA
-
Apr 28, 2026, 15:07Stan Van Boeckel: Pitfalls in Early Drug Discovery
-
Apr 28, 2026, 15:02Stephani Carolina Salvatierra Moreno: Our Study on Microneedling and PRP Has Been Published
-
Apr 28, 2026, 14:57Steven Heylen: Hydrolyzed Collagen Injections for Knee Osteoarthritis as a New Treatment Option
-
Apr 28, 2026, 14:22Heghine Khachatryan: Regarding Coagulation Factor Dynamics During Pregnancy in Hemophilia B Carriers